Injection site pain and drugs of ingredients of nabumetone - a phase IV clinical study of FDA data


Summary:

Injection site pain is found among people who take drugs with ingredients of nabumetone, especially for people who are female, 60+ old . This phase IV clinical study is created by eHealthMe based on reports of 14,287 people who have side effects when taking drugs with ingredients of nabumetone from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Nabumetone, Relafen.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Feb, 07, 2023

14,287 people reported to have side effects when taking drugs with ingredients of nabumetone.
Among them, 271 people (1.9%) have Injection site pain


What is Injection site pain?

Injection site pain is found to be associated with 2,451 drugs and 1,831 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of nabumetone cause Injection site pain?

Gender of people who have Injection site pain when taking drugs with ingredients of nabumetone *:

  • female: 84.76 %
  • male: 15.24 %

Age of people who have Injection site pain when taking drugs with ingredients of nabumetone *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 4.35 %
  • 20-29: 3.48 %
  • 30-39: 10.0 %
  • 40-49: 17.39 %
  • 50-59: 31.74 %
  • 60+: 33.04 %

Conditions people have *:

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 143 people, 52.77%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 37 people, 13.65%
  3. High Blood Pressure: 35 people, 12.92%
  4. High Blood Cholesterol: 26 people, 9.59%
  5. Depression: 21 people, 7.75%
  6. Psoriasis (immune-mediated disease that affects the skin): 18 people, 6.64%
  7. Insomnia (sleeplessness): 14 people, 5.17%
  8. Stress And Anxiety: 14 people, 5.17%
  9. Ankylosing Spondylitis (type of arthritis affecting the spine): 12 people, 4.43%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 4.43%

Other drugs people take *:

  1. Humira: 150 people, 55.35%
  2. Methotrexate: 82 people, 30.26%
  3. Enbrel: 55 people, 20.30%
  4. Folic Acid: 39 people, 14.39%
  5. Vitamin D: 26 people, 9.59%
  6. Prednisone: 22 people, 8.12%
  7. Synthroid: 22 people, 8.12%
  8. Prilosec: 15 people, 5.54%
  9. Metformin: 15 people, 5.54%
  10. Plaquenil: 15 people, 5.54%

Other side effects people have besides Injection site pain *:

  1. Joint Pain: 38 people, 14.02%
  2. Injection Site Erythema (redness at injection site): 33 people, 12.18%
  3. Injection Site Bruising: 29 people, 10.70%
  4. Pain In Extremity: 21 people, 7.75%
  5. Injection Site Haemorrhage (bleeding from injection site): 20 people, 7.38%
  6. Headache (pain in head): 18 people, 6.64%
  7. Nausea (feeling of having an urge to vomit): 16 people, 5.90%
  8. Drug Ineffective: 16 people, 5.90%
  9. Fatigue (feeling of tiredness): 15 people, 5.54%
  10. Injection Site Reaction: 15 people, 5.54%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Drugs with ingredients of nabumetone, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on nabumetone. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: